Tau Protein's Misfolding Mystery: Unraveling the Differing Folds in Neurodegenerative Diseases
"New research sheds light on how the tau protein folds differently in various neurodegenerative diseases, paving the way for targeted therapies."
Neurodegenerative diseases, including Alzheimer's disease, are a growing global health concern, affecting millions worldwide. At the heart of many of these conditions lies a common culprit: the tau protein. While tau protein plays a crucial role in stabilizing microtubules within neurons, its misfolding and aggregation can lead to devastating consequences.
Recent research has illuminated a critical aspect of tau protein behavior: it folds differently depending on the specific neurodegenerative disease in question. This discovery, published in Nature Reviews Neurology, marks a significant step forward in understanding the complexities of these diseases and opens new avenues for targeted therapeutic interventions.
This article will delve into the nuances of tau protein misfolding, exploring its implications for disease progression and highlighting the potential for innovative treatment strategies. By understanding the specific folds of tau in different diseases, researchers hope to develop therapies that can precisely target and correct these abnormalities.
Tau as a Disease Biomarker
Tau is mainly expressed in neurons of the central nervous system, where it supports axonal maintenance and transport. Tau protein measurement in biospecimens has emerged as a fundamental tool for the accurate diagnosis of Alzheimer’s disease. Studies have also reported abnormal tau findings across various neurodegenerative diseases. In Alzheimer’s disease and other tauopathies, abnormal post-translational modifications can cause tau to form oligomers or fibrous aggregates.
From Detection to Mechanism
Current approaches center on identifying abnormal tau deposition, post-translational modifications, oligomers, and fibrous aggregates. Tauopathies are associated with tau dysfunction and insoluble tau accumulation in the brain at autopsy. Evidence from human disease and nonclinical translational models supports a central pathological role for tau, historically understood mainly as a toxic gain of function. However, tau-targeting strategies reflect an evolving field, and the available source material does not establish that one approach resolves all limitations.
Tracing Tau’s Discovery
A paired helical filament protein was identified in neurofibrillary tangles in Alzheimer disease brains in 1974. In 1975, tau was isolated from porcine brain as a microtubule-associated factor. Researchers established in 1986 that the paired helical filament protein and tau were the same protein. These milestones connected a normal microtubule-associated protein with the filamentous lesions characteristic of Alzheimer disease.
The Role of Tau Protein in Healthy Neurons
In healthy neurons, tau protein acts as a vital stabilizer for microtubules, which are essential components of the cell's cytoskeleton. Microtubules serve as tracks for transporting nutrients, organelles, and other crucial substances throughout the neuron. Tau binds to these microtubules, maintaining their structural integrity and ensuring efficient cellular transport.
- Normal Tau: Stabilizes microtubules, aiding in intracellular transport.
- Misfolded Tau: Detaches from microtubules, forming toxic aggregates.
- Neurofibrillary Tangles: Disrupt neuronal function, leading to cell death.
Distinct Filament Folds
Cryo-electron microscopy and atomic modelling revealed that tau filaments in Pick disease have a distinct protein structure from those observed in Alzheimer disease. Work by Michel Goedert, Sjors Scheres, and colleagues at the Medical Research Council Laboratory of Molecular Biology, together with collaborators at Indiana University School of Medicine, provided this structural insight. Later findings suggested a hierarchical classification of tauopathies based on filament folds. That framework can complement clinical diagnosis and neuropathology and may identify new entities, including a case diagnosed as progressive supranuclear palsy whose filament structures were intermediate between globular glial tauopathy and progressive supranuclear palsy.
Limits and Open Questions
A correction notice for the 2018 Nature Reviews Neurology article reported that Michel Goedert’s first name and Sjors Scheres’s affiliation were incorrect in the original online version. Beyond publication details, tau research faces biological complexity: abnormal phosphorylation can contribute to insoluble aggregates and neuronal dysfunction, while tau also has crucial roles in neuronal integrity. Reviews describe several possible intervention strategies, including reducing phosphorylation, inhibiting aggregation, and enhancing clearance. These challenges show why a single explanation or therapeutic target may not fully account for tau-related neurodegeneration.
One Protein, Multiple Diseases
Tau was first identified in 1975 and was implicated in Alzheimer’s disease 10 years later. By 1991, filamentous tangle inclusions were known to contain hyperphosphorylated tau, and similar inclusions became associated with other neurodegenerative diseases. Tau is the major component of intracellular filamentous deposits in Alzheimer’s disease, progressive supranuclear palsy, corticobasal degeneration, Pick’s disease, argyrophilic grain disease, and inherited frontotemporal dementia and parkinsonism linked to chromosome 17. The range of diseases associated with these deposits illustrates that tau pathology is shared across disorders but appears in distinct clinical and pathological settings.
Future Directions: Targeted Therapies for Tauopathies
The discovery that tau protein folds differently in various neurodegenerative diseases offers a promising avenue for developing targeted therapies. By identifying the specific folds associated with each disease, researchers can design molecules that selectively bind to and correct these aberrant structures. This approach holds the potential to prevent or reverse the formation of neurofibrillary tangles, slowing down or halting disease progression.
Tau’s Network of Interactions
Tau-related protein-protein interactions are essential for brain function. According to the 2025 review, dysregulation of these interactions is associated with neurodegenerative illnesses. Pathogenic tau forms arising through interactions with different proteins may contribute to disease development or aggravation through aggregation and inflammation. Tau is therefore considered both a biomarker for Alzheimer’s disease onset and a potential therapeutic target, although its broader interaction network complicates the picture.
Targeting Mitochondrial Stress
A study highlighted by the National Institutes of Health suggests that abnormal tau proteins involved in certain neurodegenerative diseases interact with mitochondria. These interactions may drive a process called reverse electron transport. The study suggests that inhibiting reverse electron transport could represent a new therapeutic strategy for brain diseases linked to abnormal tau. This direction expands tau research beyond aggregation toward mitochondrial mechanisms.
Beyond Toxic Gain of Function
Tauopathies are defined by tau dysfunction and insoluble tau accumulation in the brain at autopsy. Evidence from human disease and nonclinical translational models indicates that tau has a central pathological role in these disorders. Historically, this role was thought to arise primarily from a toxic gain of function. The review also indicates that tau-targeting research is evolving, leaving open questions about how tau’s different pathological effects should be addressed.
A Changing View of Tau
A Stanford Medicine-led study described in August 2026 presents a paradigm shift in understanding tau, a protein linked to Alzheimer’s disease and other neurodegenerative disorders. The report indicates that tau may have a role beyond its established association with disease pathology. This changing view could affect how researchers interpret tau-related mechanisms and therapeutic opportunities. The source material does not provide further clinical outcome details, so the real-world implications remain to be established.